HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The Phase 1b part of this clinical trial is to investigate the safety and pharmacokinetic
(PK) characteristics of HTMC0435 tablets combined with temozolomide in patients with various
advanced solid tumors (recurrent small cell lung cancer is preferred). The Phase 2 part of
the study is a multi-center, open-label, single-arm trial to investigate the preliminary
efficacy of HTMC0435 and temozolomide in patients with recurrent small cell lung cancer
(SCLC) at the recommended phase 2 dose.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.